S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Hologic Stock Forecast, Price & News

+1.92 (+2.56%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.48 million shs
Average Volume
1.98 million shs
Market Capitalization
$19.32 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

Hologic logo

About Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment comprises products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.


Hologic: Still Going Strong - Seeking Alpha
November 28, 2021 |  seekingalpha.com
Hologic Updates Key Risk Factors - Nasdaq
November 23, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

X-ray apparatus & tubes
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$5.63 billion
Cash Flow
$10.48 per share
Book Value
$16.78 per share


Net Income
$1.87 billion
Pretax Margin




Free Float
Market Cap
$19.32 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.31 out of 5 stars

Medical Sector

268th out of 1,391 stocks

X-Ray Apparatus & Tubes Industry

1st out of 6 stocks

Analyst Opinion: 2.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Hologic (NASDAQ:HOLX) Frequently Asked Questions

Is Hologic a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hologic stock.
View analyst ratings for Hologic
or view top-rated stocks.

How has Hologic's stock price been impacted by Coronavirus?

Hologic's stock was trading at $43.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HOLX stock has increased by 75.5% and is now trading at $76.83.
View which stocks have been most impacted by COVID-19

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Hologic

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Sunday, October, 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.60. The medical equipment provider had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.04 billion. Hologic had a trailing twelve-month return on equity of 57.61% and a net margin of 33.22%. The firm's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.07 earnings per share.
View Hologic's earnings history

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its first quarter 2022 earnings guidance on Monday, November, 8th. The company provided earnings per share (EPS) guidance of $1.150-$1.250 for the period, compared to the Thomson Reuters consensus estimate of $0.960. The company issued revenue guidance of $1.10 billion-$1.15 billion, compared to the consensus revenue estimate of $991.63 million.

What price target have analysts set for HOLX?

10 brokerages have issued twelve-month price targets for Hologic's shares. Their forecasts range from $76.00 to $100.00. On average, they expect Hologic's stock price to reach $87.90 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price.
View analysts' price targets for Hologic
or view top-rated stocks among Wall Street analysts.

Who are Hologic's key executives?

Hologic's management team includes the following people:
  • Stephen P. MacMillan, Chairman, President & Chief Executive Officer
  • Karleen Marie Oberton, Chief Financial Officer
  • Jay A. Stein, Chairman-Emeritus, Chief Technology Officer & SVP
  • Patricia K. Dolan, Secretary & Vice President
  • Jan Verstreken, Group President-International

What is Steve MacMillan's approval rating as Hologic's CEO?

283 employees have rated Hologic CEO Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among Hologic's employees.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.42%), Wellington Management Group LLP (2.59%), Geode Capital Management LLC (2.13%), Parnassus Investments LLC (1.63%), Nordea Investment Management AB (1.04%) and Barrow Hanley Mewhinney & Strauss LLC (0.99%). Company insiders that own Hologic stock include Benjamin Jordan Cohn, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty and Stephen P Macmillan.
View institutional ownership trends for Hologic

Which institutional investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Invesco Ltd., State of Michigan Retirement System, Sumitomo Mitsui Trust Holdings Inc., Janus Henderson Group PLC, and Balyasny Asset Management LLC. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Kevin R Thornal, and Sean S Daugherty.
View insider buying and selling activity for Hologic
or view top insider-selling stocks.

Which institutional investors are buying Hologic stock?

HOLX stock was bought by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Caisse DE Depot ET Placement DU Quebec, Nordea Investment Management AB, Retirement Systems of Alabama, Russell Investments Group Ltd., Jennison Associates LLC, NN Investment Partners Holdings N.V., and AustralianSuper Pty Ltd.
View insider buying and selling activity for Hologic
or or view top insider-buying stocks.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $76.83.

How much money does Hologic make?

Hologic has a market capitalization of $19.32 billion and generates $5.63 billion in revenue each year. The medical equipment provider earns $1.87 billion in net income (profit) each year or $7.20 on an earnings per share basis.

How many employees does Hologic have?

Hologic employs 6,705 workers across the globe.

Does Hologic have any subsidiaries?

The following companies are subsidiares of Hologic: Focal Therapeutics.

When was Hologic founded?

Hologic was founded in 1985.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

Where are Hologic's headquarters?

Hologic is headquartered at 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at (508) 263-2900, via email at [email protected], or via fax at 781-890-8031.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.